趋化因子配体18表达水平对胰腺癌患者的预后价值  

Value of the levels of CCL18 expression in pancreatic ductal adenocarcinoma for the patients＇ prognosis

作　　者：郭欣[1] 吕行[1] 谢娇贵 乔勃伟 殷若哲 方诚[1] 吕小慧[1] 陈勇[1] 

机构地区：[1]第四军医大学西京医院肝胆外科,西安710032

出　　处：《中华肝胆外科杂志》2015年第7期474-477,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：国家自然科学基金（81372607、81070363）

摘　　要：目的研究趋化因子配体18（CCL18）在胰腺癌组织中的表达及其与患者预后的关系。方法收集2012年3月至2013年8月第四军医大学西京医院肝胆外科手术后病理诊断为胰腺导管腺癌（PDAC）患者的肿瘤组织标本和癌旁组织标本各60例，以免疫组织化学染色法检测CCL18在胰腺癌组织和癌旁非癌组织中的表达情况。结果CCL18在胰腺癌肿瘤组织的表达显著高于癌旁非癌组织（P〈0．05），且其在胰腺癌组织的表达水平随着临床分期的增加而升高。结论CCL18可作为胰腺癌的标志物之一。其表达水平对于胰腺癌的治疗和预后有重要意义。Objective To investigate the expression of CCL18 in pancreatic ductal adenocarcinoma （PDAC） and the relationship between its expression level and prognosis. Methods Sixty tumor tissues and their matched adjacent noncancerous tissues of the patients with PDAC diagnosed in our hospital were collec- ted from March 2012 to August 2013. Immunochemistry was performed to investigate the expression levels of CCL18 in the tissues. Results CCL18 exhibited higher expression levels in the PDAC tissues than in the adjacent noncancerous tissues （P 〈 0. 05 ）. In addition, the levels of CCL18 significantly increased with pro- gression of the clinical staging. Conclusion CCL18 could be a potential biomarker for PDAC and its ex- pression level played an important role in the prognosis of PDAC.

关 键 词：趋化因子配体18 胰腺癌 生存分析 临床分期 预后 

分 类 号：R735.2[医药卫生—肿瘤]